Endovascular Treatment for Worsening Mild Basilar Artery Blockage Stroke
Tests endovascular treatment added to medical care in adults with worsening mild basilar artery stroke.
Plain-language title generated from the registry record
Registry title: Rescue Endovascular Treatment After Neurological Deterioration in Initially Mild Basilar Artery Occlusion in an Extended Time Window
Key facts
- Where
- Hefei and Wuhu, ChinaSee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose mild stroke from a blocked basilar artery in the brain got much worse 24 hours to 7 days later. It tests a procedure to clear the blocked artery.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- The stroke started mild (initial NIHSS score under 6). The basilar artery, or the vertebral artery leading to it, is blocked. Then it got much worse 24 hours to 7 days after it began: NIHSS score of 10 or more, with a rise of at least 4 points in total NIHSS or at least 2 points in the level-of-consciousness score. The brain scan score (pc-ASPECTS) must be 6 or higher. Randomization must happen within 24 hours of the worsening.
- Earlier treatment
- No earlier endovascular treatment for this stroke.
Main reasons for not taking part
- Worsening caused by bleeding in the brain, brain swelling or another clear cause
- Disability before the stroke (prestroke mRS above 2)
- Bleeding in the brain in the past 6 months, or other recent or active bleeding
- Pregnancy or breastfeeding
- Life expectancy under 6 months
Read by machine on 9 November 2026.
Where in China
- The First Affiliated Hospital of the University of Science and Technology of ChinaHefei, ChinaTaking people
- First Affiliated Hospital of Wannan Medical CollegeWuhu, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- First Affiliated Hospital of Wannan Medical College
- Trial code
- NCT06843356
- Record updated
- 16 September 2026
- Original description
A prospective, multicenter, open-label, blinded-endpoint, randomized controlled trial to evaluate whether best medical management (BMM) combined with endovascular therapy (EVT) improves neurological outcomes compared to BMM alone in patients with progressive acute mild ischemic stroke due to basilar artery occlusion within an extended time window.Read full original descriptionShow less
Rescue Endovascular Treatment After Neurological Deterioration in Initially Mild Basilar Artery Occlusion in an Extended Time Window
A prospective, multicenter, open-label, blinded-endpoint, randomized controlled trial to evaluate whether best medical management (BMM) combined with endovascular therapy (EVT) improves neurological outcomes compared to BMM alone in patients with progressive acute mild ischemic stroke due to basilar artery occlusion within an extended time window.
Inclusion: Age ≥18 years; Initially mild ischemic stroke, defined as an initial NIHSS score <6, with no prior endovascular treatment for the index ischemic event; Basilar artery occlusion, or vertebral artery occlusion resulting in complete interruption of antegrade flow into the basilar artery, documented by CTA, MRA, or DSA during the initially mild phase and before qualifying neurological deterioration; Qualifying neurological deterioration occurring between 24 hours and 7 days after initial symptom onset, or after the last known well if symptom onset is unknown; Qualifying neurological deterioration is defined as an NIHSS score ≥10 with either a ≥4-point increase in total NIHSS or a ≥2-point increase in the NIHSS level-of-consciousness score from the initial NIHSS score and must be documented by certified medical personnel at a medical facility, including a referring hospital; Posterior circulation Acute Stroke Prognosis Early CT Score (pc-ASPECTS) ≥6 on noncontrast CT or diffusion-weighted MRI performed after qualifying neurological deterioration; Time from qualifying neurological deterioration to randomization ≤24 hours; Written informed consent obtained from the patient or a legally authorized representative.
Exclusion: Concurrent anterior and posterior circulation strokes; Prior imaging confirmed or investigator-assessed chronic basilar artery occlusion; Symptom progression due to intracranial hemorrhage, brain edema, or other clear causes (including but not limited to infarct hemorrhagic transformation, new infarction in non-occluded vascular regions, obstructive hydrocephalus, severe infection, high fever, heart or kidney dysfunction, hypovolemia, or severe electrolyte disturbances); Intracranial hemorrhage within the past 6 months, including parenchymal brain hemorrhage, intraventricular hemorrhage, or subarachnoid hemorrhage; Gastrointestinal or urinary tract bleeding, acute myocardial infarction, cranial trauma, or major surgery within the past month; Presence of active bleeding, coagulation disorders, or uncorrectable bleeding tendencies; Severe heart, liver, or kidney dysfunction or other severe systemic late-stage diseases; Known allergy to iodine contrast agents or other treatment-related drugs; Medically uncontrolled refractory hypertension (defined as persistent systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg) (Note: Participants can be included if their blood pressure is controllable with medication and maintained at an acceptable level); Investigator's judgment that the patient is unsuitable for participation in this study or may face significant risks (e.g., due to mental illness, cognitive, or emotional disorders preventing understanding and/or compliance with study procedures and/or follow-up); Platelet count <40×10\^9/L, or INR >2 during anticoagulation therapy (irreversible); Uncontrollable blood glucose <2.8 mmol/L or >22.2 mmol/L; prestroke mRS >2; Factors in the target vessel that are expected to prevent completion of endovascular treatment; Presence of untreated intracranial aneurysms, intracranial tumors (except small meningiomas), or intracranial vascular malformations; Pregnancy or breastfeeding; Life expectancy <6 months; Participation in other clinical studies that may affect outcome assessment.